Flossbach Von Storch SE Has $108.16 Million Stock Position in Stryker Corporation $SYK

Flossbach Von Storch SE lowered its holdings in shares of Stryker Corporation (NYSE:SYK) by 28.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 273,380 shares of the medical technology company’s stock after selling 106,355 shares during the period. Flossbach Von Storch SE owned about 0.07% of Stryker worth $108,157,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Nuveen LLC acquired a new position in Stryker during the 1st quarter worth about $558,075,000. Price T Rowe Associates Inc. MD increased its stake in shares of Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after buying an additional 1,021,496 shares during the period. Alliancebernstein L.P. raised its position in shares of Stryker by 66.7% during the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock worth $511,152,000 after acquiring an additional 549,643 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Stryker by 1.1% in the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after acquiring an additional 361,136 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Stryker by 13.1% in the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock valued at $838,640,000 after acquiring an additional 261,058 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Barclays raised their price target on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Wells Fargo & Company increased their price objective on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Truist Financial reissued a “hold” rating and set a $392.00 target price (down previously from $407.00) on shares of Stryker in a research note on Monday, November 3rd. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Stryker in a research report on Monday, November 3rd. Finally, Redburn Partners set a $420.00 price target on Stryker in a report on Thursday, September 18th. Fourteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $433.37.

Stryker Trading Up 0.5%

NYSE:SYK opened at $355.74 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $136.04 billion, a price-to-earnings ratio of 47.12, a PEG ratio of 2.66 and a beta of 0.94. The firm has a fifty day simple moving average of $374.63 and a two-hundred day simple moving average of $381.22. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating the consensus estimate of $3.13 by $0.06. The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the transaction, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 520,500 shares of company stock worth $184,803,065. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.